论文部分内容阅读
目的:分析孟鲁司特氨溴特罗治疗患有咳嗽变异性哮喘儿童的效果。方法:在患有咳嗽变异性哮喘的儿童中抽取36例,依照用药区分为甲、乙、丙三组,甲组12例选用孟鲁司特,乙组12例选用氨溴特罗,丙组12例同时选用孟鲁司特和氨溴特罗。对用药后的各组进行不同时间的C—ACT测评,并通过计算不同时间的PEF变异率来观察对比肺功能。结果:(1)C—ACT测评:15天后对比甲、乙、丙三组的测评分数,丙组比甲、乙两组高,(P0.05)。30天后对比甲、乙、丙三组的测评分数,甲、乙、丙三组无明显差异(P>0.05)。(2)PEF变异率统计:15天后对比甲、乙、丙三组的统计值,丙组比甲、乙两组低,(P0.05)。30天后分别对比甲、乙、丙三组的统计值,甲、乙、丙三组无明显差异(P>0.05)。结论:将孟鲁司特与氨溴特罗联合用于咳嗽变异性哮喘患儿的治疗具有协同增效的作用。
OBJECTIVE: To analyze the efficacy of montelukast ambroxol in the treatment of children with cough variant asthma. Methods: Thirty-six children with cough-variant asthma were randomly divided into three groups: A, B and C, montelukast in 12 cases in group A, ambroxol in group B in 12 cases, Twelve patients selected montelukast and ambroxol simultaneously. C-ACT was evaluated at different time points after treatment, and lung function was observed and compared by calculating PIF variation rate at different time points. Results: (1) C-ACT test: The scores of A, B and C were compared 15 days later, group C was higher than group A and group B (P <0.05); There was no significant difference between group A and group B (P> 0.05). After 30 days, the scores of A, B and C in three groups were not significantly different (P> 0.05). (2) Statistics of variation rate of PEF: The statistics of A, B and C groups were compared 15 days later, group C was lower than group A and group B (P <0.05); There was no significant difference between group A and group B > 0.05). After 30 days, the statistics of A, B and C groups were compared. There was no significant difference between A, B and C groups (P> 0.05). CONCLUSIONS: The combination of montelukast and ambroxol has synergistic effects in the treatment of children with cough variant asthma.